Thomas J. Schall - Aug 4, 2022 Form 4 Insider Report for ChemoCentryx, Inc. (CCXI)

Role
President and CEO, Director
Signature
/s/ Susan M. Kanaya, as Attorney-in-Fact
Stock symbol
CCXI
Transactions as of
Aug 4, 2022
Transactions value $
-$4,675,333
Form type
4
Date filed
8/8/2022, 07:41 PM
Previous filing
Feb 25, 2022
Next filing
Oct 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCXI Common Stock Options Exercise $1.86M +130K +5.43% $14.28 2.52M Aug 4, 2022 Direct
transaction CCXI Common Stock Sale -$6.53M -130K -5.15% $50.24 2.39M Aug 4, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCXI Stock Option (right to buy) Options Exercise -130K -78.79% 35K Aug 4, 2022 Common Stock 130K $14.28 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $50.05 to $50.59 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F3 As of August 4, 2022, and prior to this transaction, the exercised options were fully vested.
F4 Not applicable.